menu
    • menu
    [{"orgOrder":0,"company":"MODAG","sponsor":"Evotec | Quotient Sciences | Nottingham University Hospitals NHS Trust","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anle138b","moa":"Synuclein alpha (SNCA)","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ Evotec | Quotient Sciences | Nottingham University Hospitals NHS Trust","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Evotec | Quotient Sciences | Nottingham University Hospitals NHS Trust"},{"orgOrder":0,"company":"MODAG","sponsor":"Evotec | Quotient Sciences | Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Anle138b","moa":"Synuclein alpha (SNCA)","graph1":"Undisclosed","graph2":"Phase I","graph3":"MODAG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ Evotec | Quotient Sciences | Teva Pharmaceutical Industries","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Evotec | Quotient Sciences | Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"MODAG","sponsor":"Michael J. Fox Foundation for Parkinson\u2019s Research","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Anle138b","moa":"Synuclein alpha (SNCA)","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ Michael J. Fox Foundation for Parkinson\u2019s Research","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Michael J. Fox Foundation for Parkinson\u2019s Research"},{"orgOrder":0,"company":"MODAG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Anle138b","moa":"Synuclein alpha (SNCA)","graph1":"Neurology","graph2":"Phase I","graph3":"MODAG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MODAG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"MODAG \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by MODAG

    Menu

    MODAG

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Evotec | Quotient Sciences | Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)

                            Details : Anle138b is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 08, 2022

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Evotec | Quotient Sciences | Teva Pharmaceutical Industries

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Evotec | Quotient Sciences | Nottingham University Hospitals NHS Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's D...

                            Details : Anle138b is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 28, 2020

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Evotec | Quotient Sciences | Nottingham University Hospitals NHS Trust

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease

                            Details : The short-term Phase 1b study with PD patients will be conducted by Quotient Sciences in e clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            MODAG

                            Germany arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            MODAG Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Mi...

                            Details : Anle138b which was administered in doses of up to 300 mg daily, demonstrated excellent safety and tolerability profiles at all dose levels and reached significantly higher plasma levels in humans than those required for full therapeutic efficacy in anima...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 05, 2020

                            Lead Product(s) : Anle138b

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Michael J. Fox Foundation for Parkinson’s Research

                            Deal Size : $1.4 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth